基本情報
- 標準SMILES
CC1=C(C)C(=O)C(C(CCCCCC(=O)O)c2ccccc2)=C(C)C1=O- InChIKey
ZBVKEHDGYSLCCC-UHFFFAOYSA-N- 分子式
- C22H26O4
- 平均分子量
- 354.4 g/mol
- 単同位体質量
- 354.18310931
概要
Seratrodast is an organic molecular entity.
名称と識別子
- 優先名称
- Seratrodast
- IUPAC
- 7-phenyl-7-(2,4,5-trimethyl-3,6-dioxocyclohexa-1,4-dien-1-yl)heptanoic acid
- 現地名
- セラトロダスト
- 英語名
- Seratrodast
- 分子式
- C22H26O4
- 分子量
- 354.44
名称と別名
名称をさらに表示
データベース識別子
- CAS
112665-43-7- PubChem CID
- 2449
- DTXSID
DTXSID4021397- ChEMBL
CHEMBL70972- ChEBI
CHEBI:32126- UNII
- 4U58JM421N
- EC Number
- 692-169-8
- Nikkaji
- J1.633.058B
物性
構造計算による物性
- XLogP
- 4.4
- 極性表面積
- 71.4 Ų
- 水素結合供与体数
- 1
- 水素結合受容体数
- 4
- 回転可能結合数
- 8
- 重原子数
- 26
- 形式電荷
- 0
- 複雑度
- 633
物理化学的性質
- 融点
- 118 · 118-120°C
- 沸点
- 522.3 · 522.3±49.0 °C(Predicted)
- 比重(密度)
- 1.14 · 1.140±0.06 g/cm3(Predicted)
- 貯蔵温度
- -20 °C · Sealed in dry,Store in freezer, under -20°C
- 溶解性
- クロロホルム(微量)、メタノール(微量)
- 酸解離定数(Pka)
- 4.76 · 4.76±0.10(Predicted)
- 外見
- 黄橙色の固体。
- 色
- 淡いオレンジから黄色
- Merck
- 14 · 14,8459
- InChI
- InChI=1S/C22H26O4/c1-14-15(2)22(26)20(16(3)21(14)25)18(17-10-6-4-7-11-17)12-8-5-9-13-19(23)24/h4,6-7,10-11,18H,5,8-9,12-13H2,1-3H3,(H,23,24)
- InChIKey
- ZBVKEHDGYSLCCC-UHFFFAOYSA-N
- SMILES
- C1(C)C(=O)C(C)=C(C(C2=CC=CC=C2)CCCCCC(=O)O)C(=O)C=1C
- CAS データベース
- 112665 · 112665-43-7(CAS DataBase Reference)
化学的性質
化学的特性Pale Orange Solid
安全と法規制
GHS分類
GHS Classification
Warning
H361 (100%): Suspected of damaging fertility or the unborn child [Warning Reproductive toxicity]
P203, P280, P318, P405, and P501 (click each P-code to see the statement)
Aggregated GHS information provided per 2 reports by companies from 1 notifications to the ECHA C&L Inventory.
危険有害性情報
安全データ
- wgk
- WGK 3
- rtecs
- DA1600050
- hs_code
- 2918.30.3000
- Hazard Classifications
- Repr. 2
- ストレージクラス
- 11 - Combustible Solids
化学と産業
薬理情報
ATC Code
R - Respiratory system
QR - Respiratory system
MeSH Pharmacological Classification
Anti-inflammatory agents that are non-steroidal in nature. In addition to anti-inflammatory actions, they have analgesic, antipyretic, and platelet-inhibitory actions. They act by blocking the synthesis of prostaglandins by inhibiting cyclooxygenase, which converts arachidonic acid to cyclic endoperoxides, precursors of prostaglandins. Inhibition of prostaglandin synthesis accounts for their analgesic, antipyretic, and platelet-inhibitory actions; other mechanisms may contribute to their anti-inflammatory effects.
Compounds that inhibit the action of prostaglandins.
Drugs that are used to treat asthma.
応用分野
用途トロンボキサンA2受容体拮抗薬気管支喘息の治療薬
説明Seratrodast, a novel benzoquinone derivative, is the first thromboxane A2 (TxA2) receptor antagonist to reach the market. It is orally active for the treatment of bronchospastic disorders such as asthma. TxA2, a metabolite of the arachidonate cascade, is involved in several cardiovascular and respiratory diseases through its potent biological effects on platelet aggregation and constriction of vascular and respiratory smooth muscles. Seratrodast potently inhibits platelet aggregation and bronchoconstriction induced by a TxA2 mimic and by a variety of spasmogenic prostanoids including PGF2α, PGD2 and 9α,11β-PGF2. Seratrodast shows excellent efficacy in asthma and has been reported to be potentially useful in hyper-responsive disorder. The R-(+)- seratrodast was reported to be the active isomer.
上流・下流製品情報
上流原料
サプライヤー50 社
関連反応
関連ノート
読み込み中…